D. Wyles

1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS

Mark Sulkowski, M. Rodríguez‐Torres, E. Läwitz et al. · Journal of Hepatology · 2012 · 41 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Gregory T. Everson, Tram T. Tran, W.J. Towner et al. · Journal of Hepatology · 2014 · 39 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study

D. Wyles, P. Ruane, Mark Sulkowski et al. · Journal of Hepatology · 2015 · 23 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials

Massimo Puoti, C. Cooper, Sulkowski et al. · Queen Mary Research Online (Queen Mary University of London) · 2014 · 22 citations

Medicine, Infectious Diseases, Pharmacology +14

1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY

E. Läwitz, D. Wyles, Mitchell Davis et al. · Journal of Hepatology · 2013 · 10 citations · Full text

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +15